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ABSTRACT
Introduction Cervical cancer is the second most common 
cancer among women in Ethiopia, India, Nigeria and 
Pakistan. Our study objective was to assess similarities 
and differences in vaccine- impact projections through 
comparative modelling analysis by independently 
estimating the potential health impact of human 
papillomavirus (HPV) vaccination.
Methods Using two widely published models (Harvard 
and Papillomavirus Rapid Interface for Modelling and 
Economics (PRIME)) to estimate HPV vaccination impact, 
we simulated a vaccination scenario of 90% annual 
coverage among 10 cohorts of 9- year- old girls from 
2021 to 2030 in Ethiopia, India, Nigeria and Pakistan. We 
estimated potential health impact in terms of cervical 
cancer cases, deaths and disability- adjusted life years 
averted among vaccinated cohorts from the time of 
vaccination until 2100. We harmonised the two models by 
standardising input data to comparatively estimate HPV 
vaccination impact.
Results Prior to harmonising model assumptions, the 
range between PRIME and Harvard models for number 
of cervical cancer cases averted by HPV vaccination 
was: 262 000 to 2 70 000 in Ethiopia; 1 640 000 to 
1 970 000 in India; 330 000 to 3 36 000 in Nigeria and 
111 000 to 1 33 000 in Pakistan. When harmonising 
model assumptions, alignment on HPV type distribution 
significantly narrowed differences in vaccine- impact 
estimates.
Conclusion Despite model differences, the Harvard and 
PRIME models yielded similar vaccine- impact estimates. 
The main differences in estimates are due to variation in 
interpretation around data on cervical cancer attribution 
to HPV- 16/18. As countries make progress towards 
WHO targets for cervical cancer elimination, continued 
explorations of underlying differences in model inputs, 
assumptions and results when examining cervical cancer 
prevention policy will be critical.
INTRODUCTION
Persistent infections with human papilloma-
virus (HPV) types 16 and 18 cause 70% of 
all cases of cervical cancer.1 2 Studies have 
shown that prophylactic HPV vaccination 
provides almost 100% protection against 
persistent infection with vaccine- targeted 
high- risk HPV strains (eg, HPV- 16, 18) and 
associated precancers if administered prior to 
Key questions
What is already known?
 ► Studies have shown that prophylactic human papil-
lomavirus (HPV) vaccination provides almost 100% 
protection against persistent infection with vaccine- 
targeted high- risk HPV strains (eg, HPV- 16, 18) and 
associated precancers if administered prior to sex-
ual initiation.
 ► Health- impact modelling has been used to project 
vaccination impact and estimate the timeline to 
eliminate cervical cancer as a public health problem 
(ie, reducing country- level annual cervical cancer 
incidence to below 4 per 100 000).
What are the new findings?
 ► The differences in outcomes between the models 
capture variation in interpretation around data on 
cervical cancer epidemiology and future demo-
graphic change.
 ► This study highlights that HPV- type distribution is a 
critical input to modelling the potential health impact 
of vaccination.
What do the new findings imply?
 ► In order to accelerate progress towards cervical can-
cer elimination, preventing cervical cancer through 
HPV vaccination will be an essential strategy, par-
ticularly given low coverage and access to cervical 
cancer screening in low- income and middle- income 
country settings.
 ► Understanding similarities and differences between 
HPV vaccination impact predicted by different mod-
els will be crucial, given that key questions about 
which countries to prioritise and which vaccination 
strategies to use will be important in an era of HPV 
vaccine dose shortages and COVID- 19- related dis-
ruptions to vaccination programmes.
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sexual initiation.3 4 The WHO has set a goal to eliminate 
cervical cancer as a public health problem by 2100, which 
involves reducing country- level annual cervical cancer 
incidence to below 4 per 100 000.5–7 However, vaccine 
coverage remains low in low- income and middle- income 
countries (LMICs) that also lack high- quality screening 
programmes.8 More than 85% of cervical cancer deaths 
occur in LMICs9 with cervical cancer being the leading 
cause of female cancer death in sub- Saharan Africa.10
Cervical cancer imposes the second greatest burden 
of cancer incidence among women in Ethiopia, India, 
Nigeria and Pakistan as well as the second greatest burden 
of cancer mortality among women in Ethiopia, India 
and Nigeria—and the fourth greatest burden of cancer 
mortality among women in Pakistan.11 The International 
Agency for Research on Cancer (IARC) estimated that 
148 000 new cases occurred and 94 000 women died from 
cervical cancer in these four countries in 2020.11 However, 
of these four countries, only Ethiopia has implemented 
nationwide HPV vaccination, with a single- age cohort 
campaign of 14- year- old girls in 2018–2019,8 12 while 
India has introduced it in a few states in 2016.13
Most new vaccine introductions in those countries have 
been supported through partnerships with the global 
community, particularly Gavi, the Vaccine Alliance, and 
the Bill and Melinda Gates Foundation (BMGF). Mathe-
matical models of the impact of HPV vaccines have been 
used to support programme monitoring and priority 
setting by Gavi and BMGF since 2011.14 The Vaccine 
Impact Modelling Consortium (VIMC) was formed 
in late 2016, with the support of Gavi and BMGF, to 
bring together two groups involved in HPV modelling, 
with others conducting impact modelling of 11 other 
vaccines.15 Additionally, by ensuring that at least two 
groups model each analysed pathogen within VIMC, 
the vaccine- impact estimates from VIMC provide an 
important opportunity to examine the parametric, struc-
tural, model and methodological uncertainty both within 
and between models.16 Comparative modelling aims to 
enhance model transparency and can help guide public 
health research and priorities.
The two HPV vaccine models in VIMC are the Papil-
lomavirus Rapid Interface for Modelling and Economics 
(hereafter PRIME), developed by a consortium of 
modellers led by the London School of Hygiene & Tropical 
Medicine and the Harvard model (hereafter Harvard), 
developed by a team of modellers at the Harvard T.H. 
Chan School of Public Health. Both models have been 
used extensively to inform decisions by Gavi,17 18 BMGF,19 
WHO20–22 and individual countries.23 24 Given that both 
models are being used to understand HPV vaccine 
impact in the same settings, it is important to quantita-
tively compare the projections made by both models and 
to understand their differences, so that model results can 
be interpreted in the context of each other.
Our study objective was to assess similarities and differ-
ences in vaccine- impact projections through compar-
ative modelling analysis by independently estimating 
the potential health impact of HPV vaccination among 
10 cohorts of 9- year- old girls from 2021 to 2030 in Ethi-
opia, India, Nigeria and Pakistan. We used a vaccination 
scenario of 90% annual coverage among 9- year- old girls, 
in alignment with the goals of the cervical cancer elimi-
nation strategy set forth by the WHO.5–7 We estimated the 
potential health impact in terms of cervical cancer cases, 
deaths and disability- adjusted life years (DALYs) averted 
among vaccinated cohorts from the time of vaccination 
until 2100 in Ethiopia, India, Nigeria and Pakistan. We 
conducted a comparative modelling analysis to infer the 
differences in the vaccine- impact estimates generated by 
the PRIME and Harvard models.
METHODS
We used the PRIME and Harvard models to project the 
impact of HPV vaccination in four high- burden coun-
tries (Ethiopia, India, Nigeria and Pakistan). Both the 
PRIME22 25 and Harvard17 23 models have been exten-
sively described and validated elsewhere; we summarise 
their main features below.
Model overview
Both the Harvard and PRIME models are static, multi-
cohort, proportional impact models that can estimate 
the impact of HPV vaccination on cervical cancer cases 
and deaths. The models estimate vaccination impact in 
terms of reductions in age- dependent cervical cancer 
incidence and mortality in direct proportion to vaccine 
efficacy against HPV- 16/18, vaccine coverage and HPV- 
type distribution.
The models assume that girls are fully immunised 
with a two- dose schedule with perfect timeliness at the 
target ages and that girls effectively immunised against 
vaccine- targeted HPV types can develop cervical cancer 
associated with non- vaccine HPV types; also, neither cross- 
protection against non- vaccine types nor indirect effects 
are assumed. The models capture burden from all HPV 
genotypes, but the impact of vaccination is limited to the 
burden caused by genotypes targeted by the vaccine. In 
this analysis, the models simulated health benefits from 
vaccination against HPV types 16 and 18. Vaccine efficacy 
against HPV- 16/18 infections is assumed to be 100%26–30 
over the lifetime. Herd effects are not considered, so the 
vaccine- impact estimates produced are conservative. The 
models assume that age- specific cervical cancer incidence 
among unvaccinated women remains constant over the 
time horizon of the model.
Data sources
Table 1 outlines the data sources used by the Harvard 
and PRIME models. Age- specific cervical cancer inci-
dence is estimated from the database of IARC.11 For the 
proportion of cancer that is attributed to the vaccine- 
covered types (eg, HPV- 16/18), PRIME uses a study by 
Serrano et al31 whose data sources include a meta- analysis 
performed by IARC32 and a retrospective cross- sectional 
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worldwide study,33 while Harvard uses the meta- analysis 
by IARC32 exclusively.
To estimate cancer mortality, the Harvard model 
assumes country- specific distributions of cancer stages.21 
The model then incorporates 5- year stage- specific 
survival probabilities for untreated and treated cervical 
cancers (by region) and treatment access proportions (by 
country). These values are combined into weighted aver-
ages to provide country- specific 5- year survival param-
eters by stage, validated against age- specific mortality 
rates.11 21 The PRIME model uses estimates of age- specific 
cervical cancer mortality from Globocan 2020.11
In the Harvard model, disability weights are assumed 
to be 0.2 for stages I–III cervical cancer and 0.4733 for 
stage IV cervical cancer, based on the Global Burden of 
Disease (GBD) studies,34 35 and all cervical cancer cases 
experienced an average of 2 years lived with disability. In 
PRIME, disability weights are also based on GBD studies 
for the different phases of cervical cancer: diagnosis 
and primary treatment phase (0.288), controlled phase 
(0.049), metastatic phase (0.451) and terminal phase 
(0.540). The disability weights and durations for the 
different phases of cervical cancer are used in estimating 
the years of life lost due to disability.
Demography
PRIME is a multiple cohort model. It calculates popula-
tion size by estimating the size of the female age cohort 
at the age of vaccination (eg, 9 years old) from World 
Population Prospects 2019 estimates.36 The size of the 
age cohort in subsequent years is then calculated by 
constructing life tables, using the time- varying probability 
of dying by age and country from the World Population 
Prospects 2019 estimates.36
In contrast, the Harvard model is a population- based 
model that uses only data from the World Population 
Prospects 2019 estimates.36 The base year (eg, 2010) is 
used for the population projections in year 0, the next 
year (eg, 2011) is used for the population projections in 
year 1 and so forth. Life tables from the WHO are used 
for calculating DALYs, but not for population projec-
tions. Demographic estimates for age- specific population 
size (in 1- year intervals) and age- specific life expectancy 
(in 5- year intervals) were from United Nations World 
Table 1 Data sources and overview of comparative analysis for Harvard and PRIME models
Feature Harvard PRIME
Model structure Proportional outcomes Proportional outcomes
Population representation Open, multi- cohort Open, multi- cohort
Representation of infection Static Static
Representation of cancer progression Country- specific distributions of 
cancer stages, assuming 2 years lived 
with disability and 5 years survival 
for individuals experiencing cancer 
mortality21
Based on Global Burden of Disease- 
prescribed durations and phases (diagnosis 
and primary treatment phase, controlled 
phase, metastatic phase and terminal 
phase)
Disability- adjusted life year estimation Based on weighted averages of Global 
Burden of Disease- prescribed weights 
for Stages I–III and Stage IV34 35
Based on Global Burden of Disease- 
prescribed weights35
Cervical cancer incidence Globocan 2020 database of IARC11 Globocan 2020 database of IARC11
Cervical cancer mortality Weighted averages of 5 year stage- 
specific survival probabilities for 
untreated and treated cervical cancers 
(by region) and treatment access 
proportions (by country)11 21
Globocan 2020 database of IARC11
Cervical cancer prevalence Not applicable Globocan 2020 database of IARC11
Population size United Nations World Population 
Prospects 2019 estimates36
United Nations World Population Prospects 
2019 estimates combined with time- 
varying, country- specific probability of 
death for projected estimates36
Life tables World Health Organization 2019 life 
tables (constant)37
Constructed with United Nations 
Population Division time- varying, country- 
specific probability of death36
HPV- 16/18 proportion Meta- analysis by IARC32 Serrano et al31 based on meta- analysis by 
IARC32 and retrospective cross- sectional 
study33
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Population Prospects 2019 estimates36 and 2019 WHO 
life tables,37 respectively. In years when no data were avail-
able, we used a growth factor calculated as a function of a 
country’s population.
Vaccination scenarios
We conducted analyses to evaluate the impact of HPV 
vaccination assuming 90% coverage of annual, routine 
vaccination of 9- year- old girls vaccinated in 2021–2030 
(ie, ten cohorts). We assumed 100% protection against 
HPV- 16 and 18 infections over the lifetime of vaccines for 
a two- dose vaccination schedule.
Model outcomes
Cervical cancer cases, deaths and DALYs averted were 
calculated in comparison with a strategy of no HPV 
vaccination in the four high- burden countries (Ethi-
opia, India, Nigeria and Pakistan) using both PRIME 
and Harvard models. Model outcomes were aggregated 
over multiple birth cohorts to capture the health benefits 
of vaccinating girls aged 9 years between 2021 and 2030 
from the time of vaccination until 2100.
Comparative analysis
The principles of our comparative modelling study are: 
(1) addressing policy questions on HPV vaccination 
impact, (2) selection of two widely published models 
(Harvard and PRIME) to estimate HPV vaccination 
impact, (3) harmonisation of input data (demography, 
prevaccination cervical cancer burden and HPV 16/18- 
type distribution) and outputs (cervical cancer cases, 
deaths and DALYs), (4) exploring variability in estimates 
of HPV vaccination impact within and between Harvard 
and PRIME models, (5) presenting the comparative 
results and (6) projecting lifetime health impact among 
adolescent girls at 90% vaccination coverage (a key objec-
tive of the global cervical cancer elimination strategy).38 
This aligns with the principles presented in the guide-
lines for multimodel comparisons of the impact of infec-
tious disease interventions.39
Model inputs, including population demography and 
HPV- 16/18- type distribution, were harmonised in order 
to evaluate model differences. Harmonisation refers 
to standardisation of input data and outputs between 
multiple models to address a research question.39 In our 
case, we standardised input data (demography, prevacci-
nation cervical cancer burden, and HPV 16/18- type distri-
bution) and outputs (cervical cancer cases, deaths and 
DALYs) in the Harvard and PRIME models to compare 
the projections in HPV vaccination impact (cases, deaths 
and DALYs averted by vaccination).
Patient and public involvement
Patients and the public were not involved in this study.
RESULTS
Descriptive model differences
Figure 1A shows the differences between the data used 
for the proportion of cervical cancer that is attributed 
to HPV- 16/18 by the two models for Ethiopia, India, 
Nigeria and Pakistan. Figure 1B compares the cohort size 
for a cohort born in 2012 (which relates to the vaccinated 
cohort of 9- year- old girls in 2021) in the two models using 
Pakistan as an example; all four countries showed similar 
differences and trends. While, on average, the differ-
ences in cohort size range from 2% to 6%, the differences 
remain small until older ages (80 years and above), when 
the differences increased due to the decreasing popula-
tion size with increasing all- cause mortality.
Cervical cancer cases, deaths and DALYs averted
Under different assumptions for HPV- 16/18- type distri-
bution and demography, the Harvard model estimated 
a greater number of cervical cancer cases averted than 
the PRIME model by 3% in Ethiopia, 20% in India, 2% 
in Nigeria and 19% in Pakistan (figure 2A). Specifically, 
the range between the PRIME model and the Harvard 
model for the potential health impact of HPV vaccination 
in terms of the number of cervical cancer cases averted 
among girls vaccinated in 2021–2030 between the year 
of vaccination and 2100 was: 262 000 to 2 70 000 in Ethi-
opia; 1 640 000 to 1 970 000 in India; 330 000 to 3 36 000 in 
Nigeria and 111 000 to 1 33 000 in Pakistan.
Figure 1 (A) Proportion of cervical cancer attributable to HPV- 16/18; and (B) population size over time for 9- year- old girls born 
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Similarly, the Harvard model estimated a greater 
number of cervical cancer deaths averted than the 
PRIME model by 15% in Ethiopia, 17% in India, 19% 
in Nigeria and 24% in Pakistan (figure 2B). Specifically, 
the estimated number of cervical cancer deaths averted 
ranged from 210 000 to 2 48 000 in Ethiopia; 1 130 000 
Figure 2 Cervical cancer cases, deaths and DALYs averted among girls vaccinated during 2021–2030 by country since 
time of vaccination until 2100: (A) cases averted; (B) deaths averted; (C) DALYs averted. DALYs, disability- adjusted life years; 
PRIME, Papillomavirus Rapid Interface for Modelling and Economics.
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to 1 350 000 in India; 254 000 to 3 14 000 in Nigeria and 
77 200 to 1 02 000 in Pakistan in the PRIME and Harvard 
models, respectively.
However, the PRIME model estimated a greater 
number of DALYs averted than the Harvard model by 
8% in Ethiopia, whereas the Harvard model estimated 
a greater number of DALYs averted than the PRIME 
model by 1% in India, 11% in Nigeria and 10% in Paki-
stan (figure 2C). Specifically, the range between the 
PRIME model and the Harvard model for the estimated 
number of cervical cancer DALYs averted was: 4 650 000 
to 5 030 000 in Ethiopia; 25 200 000 to 25 400 000 in India; 
5 160 000 to 5 770 000 in Nigeria and 1 830 000 to 2 040 000 
in Pakistan.
Vaccination impact
Figure 3 shows the number of cervical cancer cases 
prevented per 1000 fully vaccinated girls in each of 
the four countries compared using both Harvard and 
PRIME models. When comparing the models under the 
respective model assumptions for HPV- type distribution 
and population demography, the estimated vaccination 
impact per 1000 fully vaccinated girls for the Harvard 
and PRIME models, respectively, was 19 versus 18 in Ethi-
opia; 20 versus 16 in India; 12 versus 12 in Nigeria and 6 
versus 5 in Pakistan. When harmonising the assumptions 
around population demography across the Harvard and 
PRIME models, the difference in the estimated number of 
cervical cancer cases given routine vaccination narrowed, 
but the difference in the estimated vaccination impact 
was slightly increased (figure 3A). However, overall, the 
effect of harmonising the assumptions around popu-
lation demography between Harvard and PRIME was 
small based on this metric, resulting in an equivalent esti-
mate of the number of cervical cancer cases averted per 
1000 fully vaccinated girls as the base case Harvard and 
PRIME models. On the other hand, when harmonising 
the assumptions around HPV- 16/18- type distribution 
between the Harvard and PRIME models (figure 3B), the 
differences in estimated vaccination impact were nearly 
eliminated. Thereby, we infer that the main difference 
in estimates for cases averted by vaccination between the 
two models is due to variations in cervical cancer attribu-
tion to HPV- 16/18.
DISCUSSION
The Harvard and PRIME models are used by both VIMC 
and other global stakeholders to project the impact of 
HPV vaccination. The two models differ in their inputs 
and assumptions for HPV- 16/18- type distribution, popu-
lation demography, cervical cancer mortality and estima-
tion of DALYs. The proportion of cervical cancers due 
to HPV- 16/18 is relatively higher in the Harvard model, 
especially for India and Pakistan, and thereby cases 
averted (figure 2A) and vaccination impact (cases averted 
per 1000 fully vaccinated girls) are relatively higher 
(figure 3) in the Harvard model for India and Pakistan. 
The difference between these two models captures vari-
ation around interpretation of input data. In the case of 
HPV- 16/18- type distribution, the Harvard model relied 
on a meta- analysis of cross- sectional high- risk HPV- 
type distribution in HPV- positive women,32 whereas the 
PRIME model relied on32 the study by Serrano et al.31 
whose data sources included the same meta- analysis32 
and a retrospective cross- sectional worldwide study,33 and 
accounts for multitype infections through proportional 
weighting attribution.31
HPV- 16/18 vaccination was estimated to avert substan-
tial numbers of cervical cancer cases, deaths and DALYs 
by both the Harvard model and the PRIME model. Both 
models provide similar results to previous analyses of 
vaccination impact in the analysed countries, including 
multicountry14 15 17–21 40 41 and single- country analyses,12 42 
most of which used earlier versions of the Harvard and 
PRIME models.
However, routine HPV vaccination has yet to be intro-
duced in any of these four high- burden countries at the 
national level (although a nationwide single- age cohort 
campaign of 14- year- old girls was conducted in Ethiopia 
in 2018–201912 and India introduced in a few states in 
201613). In order to accelerate progress towards cervical 
cancer elimination, preventing cervical cancer through 
HPV vaccination will be an essential strategy in these 
Figure 3 Cervical cancer cases averted per 1000 fully vaccinated girls for cohorts vaccinated during 2021–2030 since time 
of vaccination to 2100: (A) with alignment on population demography; and (B) with alignment on HPV 16/18- type distribution. 
HPV, human papillomavirus; PRIME, Papillomavirus Rapid Interface for Modelling and Economics.
 on N
ovem









ealth: first published as 10.1136/bm






Portnoy A, et al. BMJ Global Health 2021;6:e006940. doi:10.1136/bmjgh-2021-006940 7
BMJ Global Health
countries, particularly given the low coverage and access 
to cervical cancer screening.8 Understanding similari-
ties and differences between HPV vaccination impact 
predicted by different models will be crucial, given that 
key questions about which countries to prioritise and 
which vaccination strategies to use will be important in 
an era of HPV vaccine dose shortages43 and COVID- 19- 
related disruptions to vaccination programmes.44 45
The size of the relevant population at each year of age 
is critical because it determines the number of people 
who are exposed to the risk of cervical cancer and can, 
therefore, be protected by vaccination. Both methods 
used to estimate the at- risk population have strengths 
and limitations. In the PRIME model, the size of the age 
cohort in subsequent years is calculated by constructing 
life tables, using the time- varying probability of dying by 
age and country from the World Population Prospects 
2019 estimates.36 The Harvard method not only captures 
such changes but also includes future population change 
due to migration, which may not reflect the same vacci-
nation status as the locally born population. In general, 
as the demography differences are minimal between the 
two models, the vaccination- impact estimates are similar 
for each country when demography is switched to align 
with the alternative model. The main driver of the differ-
ences in the vaccination impact was HPV- 16/18- type 
distribution—or, the proportion of cervical cancers that 
can be averted by the bivalent vaccine, which has a direct 
relationship with vaccination impact. As cervical cancer 
deaths are directly estimated from cervical cancer cases, 
HPV- 16/18- type distribution is likewise the main driver of 
the differences in vaccination impact in terms of cervical 
cancer deaths averted, with additional differences due 
to the mortality estimation approach: stage- specific 
(Harvard) versus age- specific (PRIME). The years lived 
with disability for the estimated cervical cancer cases and 
the years of life lost for the estimated cervical cancer 
deaths both contribute to the estimates of DALYs averted 
by HPV vaccine, and, therefore, are likewise driven by 
differences in HPV- 16/18- type distribution. However, the 
disability weights assumed by the Harvard and PRIME 
models differ and contribute to additional differences.
This comparative modelling exercise highlighted 
differences in the estimates of health impact of HPV 
vaccination due to model uncertainty. We note that HPV 
vaccine projections are particularly susceptible to large 
swings in estimated health outcomes due to even small 
changes in fertility and mortality because of the long time 
horizons needed in the models. Comparative modelling 
exercises as we have done can enhance model trans-
parency and clarify the range of uncertainty in vaccine 
impact. Hence, the differences between the models are a 
strength that reflects the variation and uncertainty in the 
projected health outcomes of vaccination impact. Under-
standing the intermodel variation improves the quality 
and coordination of vaccine- impact assessment, which in 
turn can help guide public health research and priorities 
in cervical cancer elimination and control.
Similar comparative modelling exercises were 
conducted to examine the timeline to cervical cancer 
elimination in LMICs.20 21 Relying on evidence synthesis 
from different models was deemed an essential aspect to 
inform strategies for cervical cancer elimination by the 
WHO.5 38 However, these analyses relied on estimations 
of age- standardised cervical cancer incidence, such that 
demographic changes were not expected to drive the 
uncertainty in the timing of elimination.
There are several important limitations to this analysis. 
As we relied on static cohort models in these analyses, we 
were only able to estimate direct effects for vaccinated 
women, which excluded additional indirect benefits from 
herd immunity for unvaccinated women. We projected 
intervention impact for only 10 cohorts of 9- year- old 
girls in four countries and assumed that cervical cancer 
incidence rates affecting these cohorts would be stable 
over the time period of the analysis. Vaccine efficacy 
against high- risk HPV types other than HPV- 16/18 (ie, 
cross- protection) was not included. We did not examine 
cervical cancer screening programmes in this analysis 
and assumed that any ongoing screening programmes 
did not change as HPV vaccination introduction and 
delivery changed. Additionally, given limited data on the 
burden of other HPV- related diseases in LMICs, we did 
not evaluate the impact HPV vaccination may have on 
non- cervical cancers in women and men.
CONCLUSION
Both models project that HPV vaccination will have a 
large impact on morbidity and mortality in the four coun-
tries we examined. The differences in outcomes between 
the models capture variation in interpretation around 
data on cervical cancer epidemiology and future demo-
graphic change. This study highlights that HPV- type 
distribution is a critical input to modelling the poten-
tial health impact of vaccination. The main difference 
in estimates for cases and deaths averted by vaccination 
between the models capture variation in interpretation 
around data on cervical cancer attribution to HPV- 16/18. 
The main differences in estimates for DALYs averted by 
vaccination between the models are due to variations 
in cervical cancer attribution to HPV- 16/18, disability 
weights, and age- specific life expectancy. Continued 
explorations of underlying differences in model inputs, 
assumptions, and results will be crucial when examining 
public health policy.
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